Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMIEL study of ramucirumab plus irinotecan in early relapsed gastric cancer after adjuvant docetaxel + S-1
jRCTs051190071Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and irinotecan in gastric cancer (GC), sponsored by Eli Lilly and Company. Primary endpoint: overall survival. Started Dec 2019; status: completed.
02
Drugs
ramucirumabirinotecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs051190071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190071.